Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Three-Arm, Randomized, Open-Label Study of Interferon Alfa Alone, CCI-779 Alone, and the Combination of Interferon Alfa and CCI-779 in First-Line Poor-Prognosis Subjects With Advanced Renal Cell Carcinoma.

Next Previous
X
Search
Trial Profile

A Phase 3, Three-Arm, Randomized, Open-Label Study of Interferon Alfa Alone, CCI-779 Alone, and the Combination of Interferon Alfa and CCI-779 in First-Line Poor-Prognosis Subjects With Advanced Renal Cell Carcinoma.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Nov 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon alpha-2a (Primary) ; Temsirolimus (Primary)
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Wyeth

    • Most Recent Events

    • 07 Mar 2010 Results from a quality-adjusted survival analysis presented at the 2010 Genitourinary Cancers Symposium
    • 05 Mar 2010 Results of an analysis of serum LDH as a predictive biomarker for mTOR inhibition in patients with mRCC were presented at ASCO 2010 Genitourinary Cancers Symposium.
    • 21 Nov 2009 New source identified and integrated (M.D. Anderson Cancer Center, 2003-0924).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top